Archive


Category: 340B

  • Study after study after study: Contract pharmacy expansion not aligned in communities 340B is meant to serve

    Evidence continues to show that 340B hospitals and their contract pharmacies are often not helping patients access their medicines, especially patients in socioeconomically disadvantaged areas. Contract pharmacies dispense 340B medicines on behalf of “covered entities,” which include certain health clinics and hospitals. In 2010, HRSA dismissed concerns raised by stakeholders about the increased program integrity […]

  • New research finds gaps in charity care provided by 340B hospitals

    The 340B program was created to support safety-net clinics and qualifying hospitals by establishing a discounted medicine program funded by biopharmaceutical manufacturers to help vulnerable patients access medicines. Unfortunately, the worst kept secret about the 340B program is the lack of clear patient benefit. There are zero patient protections and zero reporting requirements for covered […]

  • 340B Court Cases

    The Public Health Service Act (PHSA) in 1992, created a program to allow hospitals providing care for underserved communities to be able to access discounted drugs. The program–known as the 340B Drug Pricing Program, has been described as follows: …[The] law requires pharmaceutical manufacturers participating in the Medicaid program to enter into a second agreement […]

  • By the numbers: Contract pharmacy participation in the 340B program

    There are many things that set the 340B program apart from other federal prescription drug programs, namely that patients are not the primary beneficiary. While in other programs, patients qualify for Medicaid or Medicare based on clear eligibility criteria, hospitals and clinics qualify for 340B based on very loose criteria and then receive discounts on […]

  • 340B 101: Three charts show the program maximizes hospitals’ bottom line with little consideration for patients

    The 340B program was created 30 years ago to support safety-net clinics and qualifying hospitals by establishing a discounted medicine program funded by biopharmaceutical manufacturers. The aim was to help vulnerable patients access medicines at these safety-net providers. Unfortunately, the program today has become largely unrecognizable as profit incentives have fueled rapid program expansion, particularly […]

  • Making medicines more affordable: Preserving safety-net programs like 340B

    Common-sense reforms can help ensure everyone benefits from America’s engine of innovation and receives the care they need and deserve. In this series, we’re taking a closer look at PhRMA’s advocacy efforts to make medicines more affordable, part of our patient-centered agenda, which aims to lower barriers between our industry’s medical innovations and patients who need […]

  • Fact Check: Do contract pharmacies help patients access 340B medicines? No.

    Over the years, there has been repeated acknowledgement that the 340B program is often not supporting the patients it was intended to help. (If you need a reminder, check out this piece in the New England Journal of Medicine or this Government Accountability Office report or even this new piece in the American Journal of […]

  • New video: Why changes to the 340B program are essential for patients

    The 340B program is confusing. That’s a fact that likely no one would question. In fact, it is often forgotten in broader discussions about our health care system even though it is the second largest federal prescription drug program. That’s a problem considering the ever-growing evidence that 340B isn’t working in the best interests of […]

  • Getting the 340B program back on track in 2021

    As our nation continues to fight a global pandemic, the need for access to affordable and quality health care feels even more pressing. This is especially true for vulnerable patients who have been disproportionately impacted by COVID-19. That’s why it has never been more important for policymakers to ensure federal programs, like the 340B program, […]

  • Growth in 340B program has not translated to improvements for patients

    Is 340B benefiting the vulnerable, uninsured patients it was designed to help? That’s the most important question policymakers should be asking in any discussion about the 340B program. Unfortunately, this program is essentially a black box with lax reporting requirements and weak oversight – which means there is little to no clear evidence that patients […]